{"id":"liposomal-cisplatin","safety":{"commonSideEffects":[{"rate":"30-90%","effect":"Nausea and vomiting"},{"rate":"20-80%","effect":"Neutropenia"},{"rate":"10-50%","effect":"Anemia"},{"rate":"5-30%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Renal impairment"},{"rate":"5-15%","effect":"Hearing loss"},{"rate":"5-10%","effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cisplatin is a DNA crosslinking agent that interferes with DNA replication and transcription, leading to cell death. The liposomal formulation helps to reduce systemic toxicity and increase the drug's accumulation in tumors.","oneSentence":"Liposomal cisplatin works by releasing cisplatin, a platinum-based chemotherapy drug, in a targeted manner to kill cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:31.003Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer"},{"name":"Non-small cell lung cancer"},{"name":"Bladder cancer"},{"name":"Stomach cancer"}]},"trialDetails":[{"nctId":"NCT07138755","phase":"PHASE2","title":"The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2025-08-29","conditions":"NSCLC, Sintilimab, Adaptive Radiotherapy","enrollment":35},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT01970722","phase":"PHASE1","title":"Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-05-19","conditions":"FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma","enrollment":40},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT07430579","phase":"NA","title":"Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"The Second Hospital of Shandong University","startDate":"2024-12-09","conditions":"Pathological Complete Remission, Objective Response Rate, Immune-related Adverse Events","enrollment":25},{"nctId":"NCT07376499","phase":"PHASE2","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2026-01-25","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT07337096","phase":"NA","title":"Electro-Acupuncture in Lung cancER : EALER Study","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2026-01","conditions":"Non Small Cell Lung Cancer, Accupuncture, PD-1 Inhibitors","enrollment":424},{"nctId":"NCT07286240","phase":"PHASE2","title":"QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2025-11-15","conditions":"Treatment of Recurrent Ovarian Cancer","enrollment":40},{"nctId":"NCT07076212","phase":"PHASE2","title":"Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-11-07","conditions":"Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma","enrollment":52},{"nctId":"NCT04580771","phase":"PHASE2","title":"A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-10-14","conditions":"Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018","enrollment":22},{"nctId":"NCT03044587","phase":"PHASE2","title":"Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-01-24","conditions":"Adenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract","enrollment":93},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT06311981","phase":"PHASE2","title":"Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-08-08","conditions":"Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy","enrollment":29},{"nctId":"NCT06292286","phase":"NA","title":"Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2023-11-01","conditions":"Recurrent Ovarian Carcinoma","enrollment":18},{"nctId":"NCT06951841","phase":"PHASE4","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2025-04-30","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT02489903","phase":"PHASE2","title":"RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)","status":"COMPLETED","sponsor":"EpicentRx, Inc.","startDate":"2015-06","conditions":"Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors","enrollment":139},{"nctId":"NCT03632798","phase":"PHASE3","title":"Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Cordgenics, LLC","startDate":"2018-08-01","conditions":"Recurrent Ovarian Cancer","enrollment":""},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":20},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT06709417","phase":"PHASE2","title":"A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-11-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":52},{"nctId":"NCT03949283","phase":"PHASE3","title":"Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cordgenics, LLC","startDate":"2019-07-26","conditions":"Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer","enrollment":150},{"nctId":"NCT05684731","phase":"PHASE1","title":"Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-02-01","conditions":"Ovarian Cancer","enrollment":30},{"nctId":"NCT06535334","phase":"","title":"Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Far Eastern Memorial Hospital","startDate":"2024-08-15","conditions":"Intravenous Chemotherapy Versus Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer","enrollment":80},{"nctId":"NCT06489808","phase":"PHASE2","title":"Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-28","conditions":"Relapsed/Refractory Large B-Cell Lymphoma","enrollment":89},{"nctId":"NCT06491134","phase":"PHASE1","title":"Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-06-27","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":12},{"nctId":"NCT06485739","phase":"PHASE4","title":"Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2024-07-01","conditions":"Neuroendocrine Tumors","enrollment":20},{"nctId":"NCT06467786","phase":"PHASE4","title":"Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-03-15","conditions":"Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT05926492","phase":"PHASE2","title":"A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-01-09","conditions":"Osteosarcoma","enrollment":160},{"nctId":"NCT06102395","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2023-05-01","conditions":"Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab","enrollment":272},{"nctId":"NCT05872724","phase":"PHASE2","title":"Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)","status":"RECRUITING","sponsor":"Suzhou Municipal Hospital","startDate":"2023-01-16","conditions":"Cervical Cancer","enrollment":32},{"nctId":"NCT03306121","phase":"PHASE3","title":"TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2017-11-13","conditions":"Nasopharyngeal Carcinoma","enrollment":322},{"nctId":"NCT05825443","phase":"PHASE2","title":"Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2023-04-10","conditions":"Immunotherapy, Chemotherapy","enrollment":57},{"nctId":"NCT05772377","phase":"PHASE2","title":"Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-07-01","conditions":"To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer","enrollment":36},{"nctId":"NCT03524508","phase":"PHASE2","title":"Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer","status":"COMPLETED","sponsor":"Changhoon Yoo","startDate":"2018-09-04","conditions":"Metastatic Biliary Tract Cancer","enrollment":178},{"nctId":"NCT05512676","phase":"","title":"Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2016-03-07","conditions":"Ovarian Neoplasm, Chemotherapeutic Toxicity, Chemotherapy Effect","enrollment":40},{"nctId":"NCT03946969","phase":"PHASE2","title":"Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2019-05-09","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT05441761","phase":"PHASE1, PHASE2","title":"Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-05-01","conditions":"Treatment, Peripheral T-cell Lymphoma","enrollment":60},{"nctId":"NCT00567567","phase":"PHASE3","title":"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-11-05","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":665},{"nctId":"NCT03983226","phase":"PHASE2","title":"Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)","status":"RECRUITING","sponsor":"Shanghai Gynecologic Oncology Group","startDate":"2019-10-18","conditions":"Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":167},{"nctId":"NCT01861496","phase":"PHASE1, PHASE2","title":"Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours","status":"COMPLETED","sponsor":"Allarity Therapeutics","startDate":"2013-04","conditions":"Phase 1: Advanced or Refractory Solid Tumours, Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer","enrollment":50},{"nctId":"NCT05244642","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2022-02-15","conditions":"Hodgkin Disease Lymphoma","enrollment":60},{"nctId":"NCT03668730","phase":"PHASE2","title":"Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-10-19","conditions":"Nasopharyngeal Carcinoma","enrollment":215},{"nctId":"NCT04998760","phase":"PHASE2","title":"A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )","status":"UNKNOWN","sponsor":"Qi Zhou","startDate":"2021-08-03","conditions":"1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer","enrollment":96},{"nctId":"NCT00859495","phase":"PHASE2","title":"Trimodal Lung-Sparing Treatment of Pleural Mesothelioma","status":"TERMINATED","sponsor":"Columbia University","startDate":"2008-02","conditions":"Pleural Mesothelioma","enrollment":9},{"nctId":"NCT00006036","phase":"PHASE1","title":"Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2000-03-22","conditions":"Head and Neck Cancer, Lung Cancer, Ovarian Cancer","enrollment":14},{"nctId":"NCT02996214","phase":"PHASE4","title":"Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)","status":"UNKNOWN","sponsor":"Nanjing Luye Sike Pharmaceutical Co., Ltd.","startDate":"2016-11","conditions":"Squamous Non-small-cell Lung Cancer","enrollment":536},{"nctId":"NCT01031420","phase":"PHASE2","title":"Dose Dense MVAC for Muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2009-12-07","conditions":"Muscle Invasive Bladder Cancer, High Risk Urothelial Carcinoma of the Upper Urinary Tracts","enrollment":54},{"nctId":"NCT03020329","phase":"PHASE2","title":"Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-11-14","conditions":"Nasopharyngeal Carcinoma, Children","enrollment":37},{"nctId":"NCT02702700","phase":"PHASE1","title":"Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2016-01","conditions":"Pleural Effusion, Malignant","enrollment":1},{"nctId":"NCT03387943","phase":"PHASE2","title":"PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2017-03-06","conditions":"Poorly Differentiated Thyroid Carcinoma","enrollment":30},{"nctId":"NCT00102531","phase":"PHASE1, PHASE2","title":"Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2005-01-12","conditions":"Osteosarcoma Metastatic","enrollment":19},{"nctId":"NCT00025259","phase":"PHASE3","title":"Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2002-09","conditions":"Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma","enrollment":1734},{"nctId":"NCT00416507","phase":"PHASE3","title":"Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2000-03","conditions":"Pancreatic Cancer","enrollment":190},{"nctId":"NCT01998347","phase":"PHASE3","title":"Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer","status":"WITHDRAWN","sponsor":"Shantou University Medical College","startDate":"2013-11","conditions":"Esophageal Cancer","enrollment":""},{"nctId":"NCT00054444","phase":"PHASE1","title":"Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2007-09","conditions":"Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer","enrollment":11},{"nctId":"NCT02142010","phase":"NA","title":"Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer","status":"UNKNOWN","sponsor":"Nanjing Luye Sike Pharmaceutical Co., Ltd.","startDate":"2014-08","conditions":"Breast Cancer","enrollment":67},{"nctId":"NCT00003896","phase":"PHASE2","title":"S9912 Combination Chemo in Stage III Ovarian Cancer,","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1999-09","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer","enrollment":68},{"nctId":"NCT00507962","phase":"PHASE1","title":"Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-03","conditions":"Advanced Cancer","enrollment":51},{"nctId":"NCT01594099","phase":"PHASE2","title":"Concurrent Chemoradiotherapy for Cervical Cancer in Elderly Women","status":"UNKNOWN","sponsor":"Xi'an Jiaotong University","startDate":"2012-04","conditions":"Cervical Cancer","enrollment":45},{"nctId":"NCT00004033","phase":"PHASE2","title":"Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"1998-09","conditions":"Malignant Mesothelioma","enrollment":30},{"nctId":"NCT00004083","phase":"PHASE2","title":"Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"1999-02","conditions":"Ovarian Cancer","enrollment":""},{"nctId":"NCT00886028","phase":"PHASE2","title":"Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma","status":"UNKNOWN","sponsor":"National Institute of Cancerología","startDate":"2006-09","conditions":"Malignant Pleural Mesothelioma","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"liposomal cisplatin","genericName":"liposomal cisplatin","companyName":"Federation Francophone de Cancerologie Digestive","companyId":"federation-francophone-de-cancerologie-digestive","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liposomal cisplatin is a small molecule modality used in combination with other treatments, such as Sintilimab and chemotherapy, to study its safety and efficacy in various conditions including Esophageal Squamous Cell Carcinoma and Pleural Mesothelioma. It is used in clinical trials, often in combination with other interventions like Liposomal Paclitaxel and Doxorubicin, to investigate its effects in potentially resectable esophageal cancer and other conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}